Roman, DL; Saldaña, SN; Nichols, DE; Carroll, FI; Barker, EL. Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. J. Pharmacol. Exp. Ther., 1 Jan 2004, 308 (2), 679–687. 519 kB. https://doi.org/10.1124/jpet.103.057836
Johnson, MP; Frescas, SP; Oberlender, R; Nichols, DE. Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: Similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). J. Med. Chem., 1 May 1991, 34 (5), 1662–1668. 975 kB. https://doi.org/10.1021/jm00109a020 #11 NMR
Monte, AP; Marona-Lewicka, D; Cozzi, NV; Nichols, DE. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. J. Med. Chem., 1 Nov 1993, 36 (23), 3700–3706. 1.0 MB. https://doi.org/10.1021/jm00075a027 #3 MS,NMR
Marona-Lewicka, D; Nichols, DE. Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur. J. Pharmacol., 1 Jun 1994, 258 (1–2), 1–13. 1.3 MB. https://doi.org/10.1016/0014-2999(94)90051-5
Marona-Lewicka, D; Kurrasch-Orbaugh, DM; Selken, JR; Cumbay, MG; Lisnicchia, JG; Nichols, DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine 1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology, 1 Oct 2002, 164 (1), 93–107. 293 kB. https://doi.org/10.1007/s00213-002-1141-z
Johnson, MP; Conarty, PF; Nichols, DE. [3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur. J. Pharmacol., 23 Jul 1991, 200 (1), 9–16. 1.1 MB. https://doi.org/10.1016/0014-2999(91)90659-E #MMAI
Huang, X; Nichols, DE. 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur. J. Pharmacol., 20 Jul 1993, 238 (2–3), 291–296. 553 kB. https://doi.org/10.1016/0014-2999(93)90859-G
Marona-Lewicka, D; Rhee, G; Sprague, JE; Nichols, DE. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol. Biochem. Behav., 1 Jan 1996, 53 (1), 99–105. 1.0 MB. https://doi.org/10.1016/0091-3057(95)00205-7
Rodríguez, GJ; Roman, DL; White, KJ; Nichols, DE; Barker, EL. Distinct recognition of substrates by the human and Drosophila serotonin transporters. J. Pharmacol. Exp. Ther., 1 Jan 2004, 306 (1), 338–346. 452 kB. https://doi.org/10.1124/jpet.103.048751
Luethi, D; Kolaczynska, KE; Docci, L; Krähenbühl, S; Hoener, MC; Liechti, ME. Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology, 15 May 2018, 134 (A), 4-12. 1.8 MB. https://doi.org/10.1016/j.neuropharm.2017.07.026 #MMAI
Simmler, LD; Liechti, ME. Pharmacology of MDMA- and amphetamine-like new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 143-164. 298 kB. https://doi.org/10.1007/164_2018_113
Marona-Lewicka, D; Nichols, DE. Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology, 1 Jul 1998, 138 (1), 67–75. 129 kB. https://doi.org/10.1007/s002130050646 #MMAI
Walline, CC; Nichols, DE; Carroll, FI; Barker, EL. Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. J. Pharmacol. Exp. Ther., 1 Jun 2008, 325 (3), 791–800. 269 kB. https://doi.org/10.1124/jpet.108.136200 #5-Methoxy-6-methyl-2-aminoindan
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Aminoindanes MMAI
Halberstadt, AL; Brandt, SD; Walther, D; Baumann, MH. 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors. Psychopharmacology, 1 Mar 2019, 236 (3), 989-999. 541 kB. https://doi.org/10.1007/s00213-019-05207-1 #MMAI
Nichols, DE; Marona-Lewicka, D; Huang, X; Johnson, MP. Novel serotonergic agents. Drug Des. Discovery, 1 Feb 1993, 9 (3–4), 299–312. 4.7 MB. #MMAI
Sainsbury, PD; Kicman, AT; Archer, RP; King, LA; Braithwaite, RA. Aminoindanes—the next wave of ‘legal highs’? Drug Test. Anal., 1 Aug 2011, 3 (7–8), 479–482. 79 kB. https://doi.org/10.1002/dta.318 #MMAI